{"id":"NCT01202760","sponsor":"Eli Lilly and Company","briefTitle":"A Rheumatoid Arthritis Study in Participants","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2012-12","completion":"2013-07","firstPosted":"2010-09-16","resultsPosted":"2018-04-25","lastUpdate":"2018-04-25"},"enrollment":1004,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"LY2127399","otherNames":["Tabalumab"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"120 mg LY2127399","type":"EXPERIMENTAL"},{"label":"90 mg LY2127399","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic drug (DMARD) therapy.\n\nThis study is comprised of 2 periods:\n\nPeriod 1 - 24-week blinded treatment\n\nPeriod 2 - 48-week post-treatment follow-up","primaryOutcome":{"measure":"Percentage of Participants With American College of Rheumatology 20% (ACR20) Response","timeFrame":"Up to 24 weeks","effectByArm":[{"arm":"120 mg LY2127399","deltaMin":34.4,"sd":null},{"arm":"90 mg LY2127399","deltaMin":33.5,"sd":null},{"arm":"Placebo","deltaMin":31.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":213,"countries":["United States","Argentina","Australia","Bulgaria","Colombia","Croatia","Hungary","India","Japan","Lithuania","Malaysia","Mexico","New Zealand","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Sri Lanka","Taiwan","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":379},"commonTop":["Upper respiratory tract infection","Rheumatoid arthritis","Nasopharyngitis","Headache","Bronchitis"]}}